Stevanato Group outlines 2026 revenue target up to €1.308B with high-value solutions set to reach 48% of sales (NYSE:STVN)

Management View - Stevanato Group reported a 9% increase in total company revenue at constant-currency rates and a 7% increase on a reported basis for fiscal 2025 compared to 2024 [2] - The company highlighted double-digit top-line growth in the Biopharmaceutical sector [2] Future Outlook - Stevanato Group has set a revenue target of up to €1.308 billion for 2026, with high-value solutions expected to account for 48% of sales [2]